# Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

> **NCT03691012** · — · UNKNOWN · sponsor: **Walter and Eliza Hall Institute of Medical Research** · enrollment: 118 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Circulating tumour DNA testing

## Key facts

- **NCT ID:** NCT03691012
- **Lead sponsor:** Walter and Eliza Hall Institute of Medical Research
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-09
- **Primary completion:** 2020-12-31
- **Final completion:** 2025-05-09
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691012, "Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03691012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*